HRP20100699T1 - Topikalni antibioticki sastav za prevenciju lajmske bolesti - Google Patents
Topikalni antibioticki sastav za prevenciju lajmske bolesti Download PDFInfo
- Publication number
- HRP20100699T1 HRP20100699T1 HR20100699T HRP20100699T HRP20100699T1 HR P20100699 T1 HRP20100699 T1 HR P20100699T1 HR 20100699 T HR20100699 T HR 20100699T HR P20100699 T HRP20100699 T HR P20100699T HR P20100699 T1 HRP20100699 T1 HR P20100699T1
- Authority
- HR
- Croatia
- Prior art keywords
- pharmaceutical composition
- weight
- use according
- topical pharmaceutical
- composition
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract 6
- 208000016604 Lyme disease Diseases 0.000 title claims abstract 4
- 230000002265 prevention Effects 0.000 title claims abstract 4
- 230000003115 biocidal effect Effects 0.000 title claims 5
- 230000000699 topical effect Effects 0.000 title 1
- 239000012049 topical pharmaceutical composition Substances 0.000 claims abstract 9
- 241000589969 Borreliella burgdorferi Species 0.000 claims abstract 4
- 239000002904 solvent Substances 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 229960004099 azithromycin Drugs 0.000 claims 3
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 claims 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 3
- 206010003399 Arthropod bite Diseases 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- 208000004374 Tick Bites Diseases 0.000 claims 2
- 239000003242 anti bacterial agent Substances 0.000 claims 2
- 230000008030 elimination Effects 0.000 claims 2
- 238000003379 elimination reaction Methods 0.000 claims 2
- 239000002562 thickening agent Substances 0.000 claims 2
- RXZBMPWDPOLZGW-XMRMVWPWSA-N (E)-roxithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=N/OCOCCOC)/[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 RXZBMPWDPOLZGW-XMRMVWPWSA-N 0.000 claims 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 claims 1
- 239000004099 Chlortetracycline Substances 0.000 claims 1
- FMTDIUIBLCQGJB-UHFFFAOYSA-N Demethylchlortetracyclin Natural products C1C2C(O)C3=C(Cl)C=CC(O)=C3C(=O)C2=C(O)C2(O)C1C(N(C)C)C(O)=C(C(N)=O)C2=O FMTDIUIBLCQGJB-UHFFFAOYSA-N 0.000 claims 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 1
- 239000004100 Oxytetracycline Substances 0.000 claims 1
- 229920006322 acrylamide copolymer Polymers 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 229920005601 base polymer Polymers 0.000 claims 1
- CYDMQBQPVICBEU-UHFFFAOYSA-N chlorotetracycline Natural products C1=CC(Cl)=C2C(O)(C)C3CC4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-UHFFFAOYSA-N 0.000 claims 1
- 229960004475 chlortetracycline Drugs 0.000 claims 1
- 235000019365 chlortetracycline Nutrition 0.000 claims 1
- CYDMQBQPVICBEU-XRNKAMNCSA-N chlortetracycline Chemical compound C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-XRNKAMNCSA-N 0.000 claims 1
- 229960002626 clarithromycin Drugs 0.000 claims 1
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 claims 1
- 229960002398 demeclocycline Drugs 0.000 claims 1
- FMTDIUIBLCQGJB-SEYHBJAFSA-N demeclocycline Chemical compound C1([C@@H](O)[C@H]2C3)=C(Cl)C=CC(O)=C1C(=O)C2=C(O)[C@@]1(O)[C@@H]3[C@H](N(C)C)C(O)=C(C(N)=O)C1=O FMTDIUIBLCQGJB-SEYHBJAFSA-N 0.000 claims 1
- 229960004100 dirithromycin Drugs 0.000 claims 1
- WLOHNSSYAXHWNR-NXPDYKKBSA-N dirithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H]2O[C@H](COCCOC)N[C@H]([C@@H]2C)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 WLOHNSSYAXHWNR-NXPDYKKBSA-N 0.000 claims 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 1
- 229940057917 medium chain triglycerides Drugs 0.000 claims 1
- 229940042016 methacycline Drugs 0.000 claims 1
- MHIGBKBJSQVXNH-IWVLMIASSA-N methacycline Chemical compound C=C([C@H]1[C@@H]2O)C3=CC=CC(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O MHIGBKBJSQVXNH-IWVLMIASSA-N 0.000 claims 1
- 229960004023 minocycline Drugs 0.000 claims 1
- DYKFCLLONBREIL-KVUCHLLUSA-N minocycline Chemical compound C([C@H]1C2)C3=C(N(C)C)C=CC(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O DYKFCLLONBREIL-KVUCHLLUSA-N 0.000 claims 1
- 229960000625 oxytetracycline Drugs 0.000 claims 1
- 235000019366 oxytetracycline Nutrition 0.000 claims 1
- IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 claims 1
- 229920000058 polyacrylate Polymers 0.000 claims 1
- 229960005224 roxithromycin Drugs 0.000 claims 1
- 229960003250 telithromycin Drugs 0.000 claims 1
- LJVAJPDWBABPEJ-PNUFFHFMSA-N telithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)[C@@H](C)C(=O)O[C@@H]([C@]2(OC(=O)N(CCCCN3C=C(N=C3)C=3C=NC=CC=3)[C@@H]2[C@@H](C)C(=O)[C@H](C)C[C@@]1(C)OC)C)CC)[C@@H]1O[C@H](C)C[C@H](N(C)C)[C@H]1O LJVAJPDWBABPEJ-PNUFFHFMSA-N 0.000 claims 1
- IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 claims 1
- 229960005041 troleandomycin Drugs 0.000 claims 1
- LQCLVBQBTUVCEQ-QTFUVMRISA-N troleandomycin Chemical compound O1[C@@H](C)[C@H](OC(C)=O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](C)C(=O)O[C@H](C)[C@H](C)[C@H](OC(C)=O)[C@@H](C)C(=O)[C@@]2(OC2)C[C@H](C)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)OC(C)=O)[C@H]1C LQCLVBQBTUVCEQ-QTFUVMRISA-N 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 239000003053 toxin Substances 0.000 abstract 1
- 231100000765 toxin Toxicity 0.000 abstract 1
- 108700012359 toxins Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Uporaba antibiotika, naznacena time, da se koristi u proizvodnji farmaceutskog sastava za prevenciju lajmske bolesti, ili za eliminaciju Borrelia burgdorferi koja je rezultat uboda krpelji, pri cemu se farmaceutski sastav treba primjenjivati topikalno. Patent sadrzi jos 9 patentnih zahtjeva.
Claims (10)
1. Uporaba antibiotika, naznačena time, da se koristi u proizvodnji farmaceutskog sastava za prevenciju lajmske bolesti, ili za eliminaciju Borrelia burgdorferi koja je rezultat uboda krpelji, pri čemu se farmaceutski sastav treba primjenjivati topikalno.
2. Farmaceutski sastav, naznačen time, da se koristi za prevenciju lajmske bolesti, ili za eliminaciju Borrelia burgdorferi (uključujući spiroketalne, cističke i/ili sferične oblike) koja je rezultat uboda krpelji, te da obuhvaća antibiotik, isparivo otapalo (definirano kao voda ili otapalo više isparivo nego voda) i opcijski sredstvo zgušnjavanja, pri čemu se farmaceutski sastav treba primjenjivati topikalno.
3. Topikalni farmaceutski sastav za uporabu prema zahtjevu 2, naznačen time, da dodatno obuhvaća neisparivo otapalo (definirano kao otapalo manje isparivo nego voda).
4. Topikalni farmaceutski sastav za uporabu prema zahtjevu 2 ili 3, naznačen time, da je antibiotik prisutan od oko 1 masenih % do oko 30 masenih %, bazirano na ukupnoj masi sastava.
5. Topikalni farmaceutski sastav za uporabu prema bilo kojem zahtjevu 2 do 4, naznačen time, da je isparivo otapalo prisutno od 40 masenih % do 99 masenih %, bazirano na ukupnoj masi sastava.
6. Topikalni farmaceutski sastav za uporabu prema bilo kojem zahtjevu 2 do 5, naznačen time, da je sredstvo zgušnjavanja prisutno od 5 masenih % do 60 masenih %, bazirano na ukupnoj masi sastava.
7. Topikalni farmaceutski sastav za uporabu prema bilo kojem zahtjevu 3 do 6, naznačen time, da je neisparivo otapalo prisutno od 2 masenih % do 30 masenih %, bazirano na ukupnoj masi sastava.
8. Topikalni farmaceutski sastav za uporabu prema bilo kojem zahtjevu 3 do 7, naznačen time, da obuhvaća azitromicinsku bazu, akrilat/akrilamid kopolimer, posebno Dermacryl 79TM , hidroksipropilnu celulozu, posebno Klucel MFTM , trigliceride srednjeg lanca, posebno MiglyolTM 812, te etanol (94%).
9. Uporaba ili topikalni farmaceutski sastav za uporabu prema bilo kojem zahtjevu 1 do 7, naznačena time, da je antibiotik odabran iz skupine koja sadrži azitromicin, klaritromicin, diritromicin, roksitromicin, telitromicin, troleandomicin, klortetraciklin, demeklociklin, minociklin, oksitetraciklin i metaciklin.
10. Uporaba ili topikalni farmaceutski sastav za uporabu prema bilo kojem zahtjevu 1 do 7, naznačena time, da antibiotik je azitromicin.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07113143 | 2007-07-25 | ||
PCT/EP2008/059696 WO2009013331A1 (en) | 2007-07-25 | 2008-07-24 | Topical antibiotic composition for the prevention of lyme disease |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20100699T1 true HRP20100699T1 (hr) | 2011-01-31 |
Family
ID=39149162
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HR20100699T HRP20100699T1 (hr) | 2007-07-25 | 2010-12-17 | Topikalni antibioticki sastav za prevenciju lajmske bolesti |
Country Status (15)
Country | Link |
---|---|
US (2) | US8710019B2 (hr) |
EP (1) | EP2079441B1 (hr) |
JP (1) | JP2010534221A (hr) |
AT (1) | ATE481964T1 (hr) |
AU (1) | AU2008280131B9 (hr) |
CA (1) | CA2694403C (hr) |
CY (1) | CY1110971T1 (hr) |
DE (1) | DE602008002692D1 (hr) |
DK (1) | DK2079441T3 (hr) |
ES (1) | ES2349906T3 (hr) |
HR (1) | HRP20100699T1 (hr) |
PL (1) | PL2079441T3 (hr) |
PT (1) | PT2079441E (hr) |
SI (1) | SI2079441T1 (hr) |
WO (1) | WO2009013331A1 (hr) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT106679B (pt) | 2012-11-27 | 2015-03-25 | Hovione Farmaciencia Sa | Formulações tópicas de tetraciclinas, sua preparação e usos |
WO2015171225A1 (en) * | 2014-05-09 | 2015-11-12 | The Johns Hopkins University | Identification of novel anti-persister activity for borrelia burgdorferi |
EP3307275B1 (en) * | 2015-06-10 | 2021-05-26 | Piedmont Animal Health Inc. | Injectable antibiotic formulations and use thereof |
EP3252470B1 (en) | 2016-06-03 | 2020-07-29 | Te?ted Oy | A method and a solid support for detecting tick-borne microbes in a biological sample |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2748399C2 (de) * | 1976-11-01 | 1983-09-15 | The Procter & Gamble Co., 45202 Cincinnati, Ohio | Antimikrobielles Mittel zur örtlichen Anwendung |
CA1165240A (en) * | 1980-07-09 | 1984-04-10 | The Procter & Gamble Company | Penetrating topical pharmaceutical compositions |
IL132096A0 (en) * | 1997-03-31 | 2001-03-19 | Johnson & Johnson Consumer | Solvent system for enhanced penetration of pharmaceutical compounds |
US7179475B1 (en) * | 1998-12-04 | 2007-02-20 | Johnson & Johnson Consumer Companies, Inc. | Anhydrous topical skin preparations |
US6239113B1 (en) * | 1999-03-31 | 2001-05-29 | Insite Vision, Incorporated | Topical treatment or prevention of ocular infections |
US6914051B1 (en) * | 2000-06-28 | 2005-07-05 | David M Allen | Penetrating antibiotic gel for soft tissue diseases |
US6589568B2 (en) * | 2001-02-16 | 2003-07-08 | Nurad, Inc. | Therapeutic body lotion containing alkali metal hypohalite |
WO2003039418A1 (en) * | 2001-11-06 | 2003-05-15 | Maxim Pharmaceuticals, Inc. | Compositions for the treatment of infectious diseases |
US8907153B2 (en) * | 2004-06-07 | 2014-12-09 | Nuvo Research Inc. | Adhesive peel-forming formulations for dermal delivery of drugs and methods of using the same |
-
2008
- 2008-07-24 AT AT08786388T patent/ATE481964T1/de active
- 2008-07-24 CA CA2694403A patent/CA2694403C/en active Active
- 2008-07-24 DK DK08786388.2T patent/DK2079441T3/da active
- 2008-07-24 SI SI200830088T patent/SI2079441T1/sl unknown
- 2008-07-24 PT PT08786388T patent/PT2079441E/pt unknown
- 2008-07-24 PL PL08786388T patent/PL2079441T3/pl unknown
- 2008-07-24 US US12/452,805 patent/US8710019B2/en active Active
- 2008-07-24 AU AU2008280131A patent/AU2008280131B9/en active Active
- 2008-07-24 JP JP2010517402A patent/JP2010534221A/ja active Pending
- 2008-07-24 EP EP08786388A patent/EP2079441B1/en active Active
- 2008-07-24 ES ES08786388T patent/ES2349906T3/es active Active
- 2008-07-24 DE DE602008002692T patent/DE602008002692D1/de active Active
- 2008-07-24 WO PCT/EP2008/059696 patent/WO2009013331A1/en active Application Filing
-
2010
- 2010-11-25 CY CY20101101077T patent/CY1110971T1/el unknown
- 2010-12-17 HR HR20100699T patent/HRP20100699T1/hr unknown
-
2014
- 2014-03-13 US US14/208,491 patent/US9610244B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US20100130437A1 (en) | 2010-05-27 |
AU2008280131A1 (en) | 2009-01-29 |
SI2079441T1 (sl) | 2010-12-31 |
ATE481964T1 (de) | 2010-10-15 |
CA2694403A1 (en) | 2009-01-29 |
US20140194375A1 (en) | 2014-07-10 |
JP2010534221A (ja) | 2010-11-04 |
ES2349906T3 (es) | 2011-01-12 |
EP2079441B1 (en) | 2010-09-22 |
PL2079441T3 (pl) | 2011-02-28 |
US8710019B2 (en) | 2014-04-29 |
DE602008002692D1 (de) | 2010-11-04 |
CA2694403C (en) | 2013-09-24 |
WO2009013331A1 (en) | 2009-01-29 |
CY1110971T1 (el) | 2015-06-11 |
PT2079441E (pt) | 2010-11-19 |
AU2008280131A8 (en) | 2010-03-04 |
AU2008280131B2 (en) | 2014-06-26 |
US9610244B2 (en) | 2017-04-04 |
EP2079441A1 (en) | 2009-07-22 |
AU2008280131B9 (en) | 2014-11-13 |
DK2079441T3 (da) | 2010-12-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20100699T1 (hr) | Topikalni antibioticki sastav za prevenciju lajmske bolesti | |
HRP20210670T1 (hr) | Pripravci za liječenje raka | |
CO6150136A2 (es) | Combinacion de adapaleno y peroxido de benzoilo para tratar lesiones de acne | |
BRPI0508561A (pt) | 3-'4-heterociclil-1,2,3-triazol-1-il-n-aril-benzamidas como inibidores da produção de citocinas para o tratamento de doenças inflamatórias crÈnicas | |
HRP20231439T1 (hr) | Oralne formulacije citidinskih analoga i postupci za njihovu uporabu | |
RS51279B (sr) | Primena hidrofilnog matriksa koji sadrži derivat poliakrilne kiseline, celulozni etar i sredstvo za raspadanje za proizvodnju leka za lečenje genitalnih poremećaja žena | |
ECSP11011278A (es) | Composición farmacéutica que comprende derivados de glucopiranosil difenilmetano, forma farmacéutica de la misma, procedimiento para su preparación y usos de la misma para el control glucémico mejorado en un paciente. | |
AR061289A1 (es) | Composiciones farmaceuticas estabilizadas que comprenden fesoterodina | |
BRPI0618211B8 (pt) | composição farmacêutica contendo pregabalina para dosagem uma vez ao dia e uso do referido composto | |
HRP20121034T1 (hr) | Lijeäśenje upalnih bolesti | |
HRP20130071T1 (hr) | Poboljšani testosteron u gelu i naäśin primjene | |
BRPI0416160A (pt) | composições de xampu antimicrobianas | |
RS51563B (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING ROOSUVASTATIN CALCIUM | |
AR059330A1 (es) | Composiciones acondicionadoras del cabello | |
HRP20140132T1 (hr) | Uporaba ulipristala za lijeäśenje uterinih fibroida | |
UY30215A1 (es) | Derivados de cromanol sustituidos, procedimientos para su preparacion, composiciones farmacéuticas que los contienen y aplicaciones | |
BR0313701A (pt) | Composição de emulsão-gel tópica compreendendo diclofenaco sódico | |
Sun et al. | Hyperoside inhibits biofilm formation of Pseudomonas aeruginosa | |
BRPI0715173A8 (pt) | Uso de uma composição de perfume para inibição da formação de amônia a partir da uréia | |
HRP20120277T1 (hr) | Sastav oktenidina | |
BR112022000957A2 (pt) | Uso de progestógeno para inibir tempestade de citocina e composição compreendendo progestógeno | |
ECSP21059181A (es) | Formulaciones agradables al paladar | |
RU2412710C2 (ru) | Применение тилвалосина в качестве противовирусного агента | |
DE602005027194D1 (de) | Buttersäurederivate, verfahren zu deren herstellung, pharmazeutische zusammensetzungen, die diese enthalten, und therapeutische anwendungen davon | |
HRP20221427T1 (hr) | Kompozicije i postupci za liječenje rana |